Clinical Scorecard: Assessment of Postoperative Pain Following Laparoscopic Radical Prostatectomy with Tranexamic Acid: Analgesic Effects or Increased Sensitivity?
At a Glance
Category
Detail
Condition
Postoperative pain and bleeding following laparoscopic radical prostatectomy
Key Mechanisms
Tranexamic acid inhibits fibrinolysis by blocking plasminogen conversion to plasmin, reducing bleeding; potential modulation of pain via inflammatory response reduction or interaction with GABA and glycine receptors affecting pain sensitivity
Target Population
Patients aged 18–75 years undergoing laparoscopic radical prostatectomy with ASA II-III status
Care Setting
Perioperative surgical care in hospital setting
Key Highlights
Tranexamic acid (TXA) reduces perioperative blood loss by antifibrinolytic action during laparoscopic radical prostatectomy.
TXA administration was associated with higher early postoperative pain scores (VAS at 0 and 6 hours) and increased rescue analgesia requirements.
No significant difference in pain scores between TXA and control groups at 12 and 24 hours postoperatively.
Guideline-Based Recommendations
Diagnosis
Use Visual Analog Scale (VAS) to assess postoperative pain at multiple time points (0, 6, 12, 24 hours).
Monitor perioperative bleeding via hemoglobin levels and clinical assessment.
Management
Administer TXA as 15 mg/kg bolus 10 minutes before incision followed by 100 mg/h infusion to reduce intraoperative bleeding.
Provide standard analgesia with tramadol and paracetamol preemptively; use dexketoprofen and paracetamol as rescue analgesics based on VAS ≥4.
Avoid nerve blocks or patient-controlled intravenous analgesia in this protocol.
Monitoring & Follow-up
Monitor hemodynamic parameters, hemoglobin levels perioperatively and postoperatively at defined intervals.
Assess pain scores regularly and record rescue analgesia timing and quantity.
Observe for side effects and adverse events related to TXA and analgesics.
Risks
Potential for increased early postoperative pain and analgesic requirements with TXA use.
Consider possible hyperalgesic effects due to TXA interaction with neurotransmitter systems.
Exclude patients with bleeding/coagulation disorders, renal failure, TXA allergy, or recent thromboembolic events.
Patient & Prescribing Data
Adults aged 18–75 years with ASA II-III undergoing laparoscopic radical prostatectomy without contraindications to TXA
TXA effectively reduces perioperative bleeding but may increase early postoperative pain and rescue analgesia needs; pain differences resolve by 12 to 24 hours postoperatively.
Clinical Best Practices
Screen patients carefully for contraindications to TXA prior to administration.
Use standardized anesthesia and analgesia protocols to allow consistent pain assessment.
Employ blinded pain assessment to reduce bias in postoperative pain evaluation.
Prepare for increased analgesic requirements in patients receiving TXA during early postoperative period.
Balance benefits of reduced bleeding with potential for increased early pain when considering TXA use.
